Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H F Staats

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|May 7, 1999
IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogensH F Staats, F A Ennis
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1993
Cytokine expression in vivo during murine herpetic stromal keratitis. Effect of protective antibody therapyH F Staats, R N Lausch
AIDS Research and Human Retroviruses|July 20, 1997
Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responsesH F Staats, S P Montgomery, T J Palker
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|March 31, 2015
Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunityD Bento, H F Staats, T Gonçalves, et al.
Journal of Virology|November 1, 1991
Anti-glycoprotein D monoclonal antibody protects against herpes simplex virus type 1-induced diseases in mice functionally depleted of selected T-cell subsets or asialo GM1+ cellsH F Staats, J E Oakes, R N Lausch
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1996
Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A)H F Staats, W G Nichols, T J Palker
Immunopharmacology|November 1, 1995
Effect of bismuth salts on systemic and mucosal immune responses to orally administered cholera toxinN S Horowitz, H F Staats, T J Palker
Infection and Immunity|November 24, 1998
Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissueA Porgador, H F Staats, Y Itoh, et al.
Journal of Lipid Research|April 1, 2000
Altered immune responses in apolipoprotein E-deficient miceD T Laskowitz, D M Lee, D Schmechel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 15, 1997
Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivoA Porgador, H F Staats, B Faiola, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Journal of Immunology (Baltimore, Md. : 1950)|May 7, 1999
IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogensH F Staats, F A Ennis
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1993
Cytokine expression in vivo during murine herpetic stromal keratitis. Effect of protective antibody therapyH F Staats, R N Lausch
AIDS Research and Human Retroviruses|July 20, 1997
Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responsesH F Staats, S P Montgomery, T J Palker
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|March 31, 2015
Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunityD Bento, H F Staats, T Gonçalves, et al.
Journal of Virology|November 1, 1991
Anti-glycoprotein D monoclonal antibody protects against herpes simplex virus type 1-induced diseases in mice functionally depleted of selected T-cell subsets or asialo GM1+ cellsH F Staats, J E Oakes, R N Lausch
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1996
Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A)H F Staats, W G Nichols, T J Palker
Immunopharmacology|November 1, 1995
Effect of bismuth salts on systemic and mucosal immune responses to orally administered cholera toxinN S Horowitz, H F Staats, T J Palker
Infection and Immunity|November 24, 1998
Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissueA Porgador, H F Staats, Y Itoh, et al.
Journal of Lipid Research|April 1, 2000
Altered immune responses in apolipoprotein E-deficient miceD T Laskowitz, D M Lee, D Schmechel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 15, 1997
Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivoA Porgador, H F Staats, B Faiola, et al.
Pageof 3